Aldo-keto reductase-7A protects liver cells and tissues from acetaminophen-induced oxidative stress and hepatotoxicity

Hepatology

Volumn 54, Issue 4, 2011, Pages 1322-1332

  Ahmed, Munzir M E ^a,b   Wang, Tao ^a   Luo, Yu ^c   Ye, Shuilong ^d   Wu, Qiao ^a   Guo, Zongsheng ^a   Roebuck, Bill D ^e   Sutter, Thomas R ^f   Yang, James Y ^a  

^a XIAMEN UNIVERSITY   (China)

^b UNIVERSITY OF GADARIF   (Sudan)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d The Third Hospital of Xiamen   (China)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF MEMPHIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDO KETO REDUCTASE 7A; DRUG METABOLITE; ENZYME; MESSENGER RNA; N ACETYL 4 BENZOQUINONEIMINE; PARACETAMOL; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL PROTECTION; ENZYME INDUCTION; GEL MOBILITY SHIFT ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIVER CELL; LIVER PROTECTION; LIVER TOXICITY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RAT; TRANSCRIPTION REGULATION; TRANSGENIC RAT;

ACETAMINOPHEN; ALCOHOL OXIDOREDUCTASES; ANIMALS; CELLS, CULTURED; DRUG-INDUCED LIVER INJURY; HEPATOCYTES; HUMANS; LIVER; MICE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY;

EID: 80053305353     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24493     Document Type: Article

References (50)

1. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis 2007; 11: 525-548, vi.
2. Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996; 271: 12063-12067.
3. Vermeulen NP, Bessems JG, Van de Straat R. Molecular aspects of paracetamol-induced hepatotoxicity and its mechanism-based prevention. Drug Metab Rev 1992; 24: 367-407.
4. Potter DW, Hinson JA. Reactions of N-acetyl-p-benzoquinone imine with reduced glutathione, acetaminophen, and NADPH. Mol Pharmacol 1986; 30: 33-41.
5. Jaeschke H, Bajt ML. Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol Sci 2006; 89: 31-41.
6. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009; 43: 342-349.
7. Bessems JG, Vermeulen NP. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit Rev Toxicol 2001; 31: 55-138.
8. Prescott LF. Paracetamol: past, present, and future. Am J Ther 2000; 7: 143-147.
9. Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008; 40: 553-624.
10. Penning TM, Drury JE. Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch Biochem Biophys 2007; 464: 241-250.
11. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. Annu Rev Pharmacol Toxicol 2007; 47: 263-292.
12. Judah DJ, Hayes JD, Yang JC, Lian LY, Roberts GC, Farmer PB, et al. A novel aldehyde reductase with activity towards a metabolite of aflatoxin B1 is expressed in rat liver during carcinogenesis and following the administration of an anti-oxidant. Biochem J 1993; 292: 13-18.
13. Ellis EM, Judah DJ, Neal GE, Hayes JD. An ethoxyquin-inducible aldehyde reductase from rat liver that metabolizes aflatoxin B1 defines a subfamily of aldo-keto reductases. Proc Natl Acad Sci U S A 1993; 90: 10350-10354.
14. Hyndman D, Bauman DR, Heredia VV, Penning TM. The aldo-keto reductase superfamily homepage. Chem Biol Interact 2003; 143-144: 621-631.
15. Knight LP, Primiano T, Groopman JD, Kensler TW, Sutter TR. cDNA cloning, expression, and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3. Carcinogenesis 1999; 20: 1215-1223.
16. Ireland LS, Harrison DJ, Neal GE, Hayes JD. Molecular cloning, expression, and catalytic activity of a human AKR7 member of the aldo-keto reductase superfamily: evidence that the major 2-carboxybenzaldehyde reductase from human liver is a homologue of rat aflatoxin B1-aldehyde reductase. Biochem J 1998; 332: 21-34.
17. Roebuck BD, Johnson DN, Sutter CH, Egner PA, Scholl PF, Friesen MD, et al. Transgenic expression of aflatoxin aldehyde reductase (AKR7A1) modulates aflatoxin B1 metabolism but not hepatic carcinogenesis in the rat. Toxicol Sci 2009; 109: 41-49.
18. Bodreddigari S, Jones LK, Egner PA, Groopman JD, Sutter CH, Roebuck BD, et al. Protection against aflatoxin B1-induced cytotoxicity by expression of the cloned aflatoxin B1-aldehyde reductases rat AKR7A1 and human AKR7A3. Chem Res Toxicol 2008; 21: 1134-1142.
19. Guengerich FP, Cai H, McMahon M, Hayes JD, Sutter TR, Groopman JD, et al. Reduction of aflatoxin B1 dialdehyde by rat and human aldo-keto reductases. Chem Res Toxicol 2001; 14: 727-737.
20. Picklo MJ, Montine TJ, Amarnath V, Neely MD. Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 2002; 184: 187-197.
21. Jin J, Krishack PA, Cao D. Role of aldo-keto reductases in development of prostate and breast cancer. Front Biosci 2006; 11: 2767-2773.
22. Praml C, Savelyeva L, Schwab M. Aflatoxin B1 aldehyde reductase (AFAR) genes cluster at 1p35-1p36.1 in a region frequently altered in human tumour cells. Oncogene 2003; 22: 4765-4773.
23. Praml C, Schulz W, Claas A, Mollenhauer J, Poustka A, Ackermann R, et al. Genetic variation of aflatoxin B1 aldehyde reductase genes (AFAR) in human tumour cells. Cancer Lett 2008; 272: 160-166.
24. Dewa Y, Nishimura J, Jin M, Kawai M, Saegusa Y, Kenmochi S, et al. Immunohistochemical analyses at the late stage of tumor promotion by oxfendazole in a rat hepatocarcinogenesis model. Arch Toxicol 2010;doi: 10.1007/s00204-010-0557-1.
25. Li D, Hinshelwood A, Gardner R, McGarvie G, Ellis EM. Mouse aldo-keto reductase AKR7A5 protects V79 cells against 4-hydroxynonenal-induced apoptosis. Toxicology 2006; 226: 172-180.
26. Gardner R, Kazi S, Ellis EM. Detoxication of the environmental pollutant acrolein by a rat liver aldo-keto reductase. Toxicol Lett 2004; 148: 65-72.
27. Hinshelwood A, McGarvie G, Ellis EM. Substrate specificity of mouse aldo-keto reductase AKR7A5. Chem Biol Interact 2003; 143-144: 263-269.
28. Macleod AK, Kelly VP, Higgins LG, Kelleher MO, Price SA, Bigley AL, et al. Expression and localization of rat aldo-keto reductases and induction of the 1B13 and 1D2 isoforms by phenolic antioxidants. Drug Metab Dispos 2010; 38: 341-346.
29. Hayes JD, Ellis EM, Neal GE, Harrison DJ, Manson MM. Cellular response to cancer chemopreventive agents: contribution of the antioxidant responsive element to the adaptive response to oxidative and chemical stress. Biochem Soc Symp 1999; 64: 141-168.
30. Ellis EM, Slattery CM, Hayes JD. Characterization of the rat aflatoxin B1 aldehyde reductase gene, AKR7A1. Structure and chromosomal localization of AKR7A1 as well as identification of antioxidant response elements in the gene promoter. Carcinogenesis 2003; 24: 727-737.
31. Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010; 13: 1665-1678.
32. Aleksunes LM, Manautou JE. Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol 2007; 35: 459-473.
33. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89-116.
34. Osburn WO, Kensler TW. Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 2008; 659: 31-39.
35. Copple IM, Goldring CE, Jenkins RE, Chia AJ, Randle LE, Hayes JD, et al. The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology 2008; 48: 1292-1301.
36. Goldring CE, Kitteringham NR, Elsby R, Randle LE, Clement YN, Williams DP, et al. Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology 2004; 39: 1267-1276.
37. Han D, Shinohara M, Ybanez MD, Saberi B, Kaplowitz N. Signal transduction pathways involved in drug-induced liver injury. Handb Exp Pharmacol 2010; 267-310.
38. Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci U S A 2001; 98: 4611-4616.
39. Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, et al. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 2001; 59: 169-177.
40. Reisman SA, Csanaky IL, Aleksunes LM, Klaassen CD. Altered disposition of acetaminophen in Nrf2-null and Keap1-knockdown mice. Toxicol Sci 2009; 109: 31-40.
41. Okawa H, Motohashi H, Kobayashi A, Aburatani H, Kensler TW, Yamamoto M. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem Biophys Res Commun 2006; 339: 79-88.
42. Reisman SA, Aleksunes LM, Klaassen CD. Oleanolic acid activates Nrf2 and protects from acetaminophen hepatotoxicity via Nrf2-dependent and Nrf2-independent processes. Biochem Pharmacol 2009; 77: 1273-1282.
43. Dewa Y, Nishimura J, Muguruma M, Matsumoto S, Takahashi M, Jin M, et al. Gene expression analyses of the liver in rats treated with oxfendazole. Arch Toxicol 2007; 81: 647-654.
44. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 2002; 62: 5196-5203.
45. Saito C, Zwingmann C, Jaeschke H. Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology 2010; 51: 246-254.
46. Taylor RC, Acquaah-Mensah G, Singhal M, Malhotra D, Biswal S. Network inference algorithms elucidate Nrf2 regulation of mouse lung oxidative stress. PLoS Comput Biol 2008; 4: e1000166.
47. Ellis EM. Protection against aflatoxin B1 in rat-a new look at the link between toxicity, carcinogenicity, and metabolism. Toxicol Sci 2009; 109: 1-3.
48. Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, et al. Nrf2, a multi-organ protector? FASEB J 2005; 19: 1061-1066.
49. Banning A, Deubel S, Kluth D, Zhou Z, Brigelius-Flohe R. The GI-GPx gene is a target for Nrf2. Mol Cell Biol 2005; 25: 4914-4923.
50. Singh A, Rangasamy T, Thimmulappa RK, Lee H, Osburn WO, Brigelius-Flohe R, et al. Glutathione peroxidase 2, the major cigarette smoke-inducible isoform of GPX in lungs, is regulated by Nrf2. Am J Respir Cell Mol Biol 2006; 35: 639-650.